DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vincristine (Vincristine) - Sepsis - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Sepsis (114)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include sepsis. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 114   Next >>

Possible Vincristine side effects in 18 year old female

Reported by a physician from Slovenia on 2012-08-23

Patient: 18 year old female

Reactions: Pulmonary Haemorrhage, Gastrointestinal Haemorrhage, Injection Site Haemorrhage, Sepsis, Shock Haemorrhagic, Acute Respiratory Distress Syndrome, Bone Marrow Failure, Staphylococcal Bacteraemia, Septic Shock

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Heparin

Vincristine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in male

Reported by a physician from United States on 2012-08-22

Patient: male

Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Mantle Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Mantle Cell Lymphoma



Possible Vincristine side effects in male

Reported by a physician from United States on 2012-08-21

Patient: male, weighing 115.7 kg (254.5 pounds)

Reactions: Gastrointestinal Haemorrhage, Cholecystitis Acute, T-Cell Lymphoma, Disseminated Intravascular Coagulation, Pancytopenia, Atrial Fibrillation, Multi-Organ Failure, Sepsis, Acute Respiratory Distress Syndrome

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Adriamycin PFS
    Indication: T-Cell Lymphoma
    Start date: 2006-09-10

Cyclophosphamide
    Indication: T-Cell Lymphoma
    Start date: 2006-01-01

Prednisone TAB
    Indication: T-Cell Lymphoma
    Start date: 2006-01-01

Remicade
    Dosage: 3 dose induction followed by maint. q 8 weeks, 300 mg on 29-jun-2006, total 27 infusions
    Indication: Rheumatoid Arthritis
    Start date: 2001-10-01
    End date: 2006-06-29

Vincristine
    Indication: T-Cell Lymphoma
    Start date: 2006-09-10

Other drugs received by patient: Azulfadine; Lisinopril



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-20

Patient:

Reactions: Multi-Organ Failure, Off Label Use, Sepsis, Cerebral Ischaemia

Adverse event resulted in: death

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: on day 1 over 15-30 minutes
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-20

Patient:

Reactions: Multi-Organ Failure, Sepsis, Cerebral Ischaemia

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-20

Patient:

Reactions: Multi-Organ Failure, Sepsis, Hypoxia, Pleural Effusion

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-20

Patient:

Reactions: Multi-Organ Failure, Sepsis, Hypoxia

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Indication: Acute Lymphocytic Leukaemia

PEG-Asparaginase
    Indication: Acute Lymphocytic Leukaemia

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-14

Patient:

Reactions: Multi-Organ Failure, Sepsis, Cerebral Ischaemia

Adverse event resulted in: death

Drug(s) suspected as cause:
Asparaginase
    Dosage: 2500 units/m2/dose as 4 weekly doses
    Indication: Acute Lymphocytic Leukaemia

Bortezomib
    Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Dosage: on day 1 over 15-30 minutes
    Indication: Acute Lymphocytic Leukaemia

Hydrocortisone
    Dosage: on days 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-13

Patient:

Reactions: Sepsis, Diffuse Large B-Cell Lymphoma Recurrent, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin
    Dosage: days 1 and 5
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Dosage: patients on r-chop received 750 mg/m2 on day 1; and acvbp received 1200 mg/m2
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: day 1,patients on r-chop recieved 50 mg/m2; and on acvbp received 75 mg/m2 on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: days 1 through 5
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: day 1, in r-chop regimen
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: day 1 in r-chop regimen
    Indication: Diffuse Large B-Cell Lymphoma

Vindesine
    Dosage: days 1 and 5
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Fluorodeoxyglucose F 18



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-31

Patient:

Reactions: Neutropenic Sepsis, Sepsis, Dyspraxia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Mabthera
    Indication: Diffuse Large B-Cell Lymphoma

Mabthera
    Indication: B-Cell Lymphoma

Prednisolone
    Dosage: on day 1-5
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-27

Patient:

Reactions: Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: B-Cell Lymphoma

Doxorubicin Hydrochloride

Prednisone
    Indication: B-Cell Lymphoma

Rituximab
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from Italy on 2012-07-27

Patient:

Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Epirubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Mabthera
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone and Prednisone
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from Italy on 2012-07-20

Patient:

Reactions: Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Mucosal Inflammation, Neurotoxicity, Sepsis, Adverse Event, Cardiotoxicity, Neutropenia, Thrombocytopenia, Diffuse Large B-Cell Lymphoma, Lymphoma, Septic Shock

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 750 mg/m2 on day 1 for chop and 750 mg/m2 on day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 50 mg/m2 on day 1 for chop and 50 mg/m2 on day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: 100 mg on days 1-5 for chop and r-chop
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: 375 mg/m2 on day 1 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: 1.4 mg/m2 on day 1 for chop and 1.4 mg/m2 on day 2 for r-chop upto a maximum dose of 2 mg
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-17

Patient:

Reactions: Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: B-Cell Lymphoma

Prednisone
    Indication: B-Cell Lymphoma

Rituxan
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Vincristine side effects in 10 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-10

Patient: 10 year old female

Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 300 mg/m2

Cyclophosphamide
    Dosage: 250 mg/m2, bid for six doses
    Indication: non-Hodgkin's Lymphoma

Cytarabine
    Dosage: 100 mg/m2, daily x 5 days
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: 30 mg/m2, single
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: 60 mg/m2, single

Hydrocortisone Acetate
    Dosage: given with methotrexate
    Indication: non-Hodgkin's Lymphoma

Hydrocortisone Acetate
    Dosage: given with cytarabine

Methotrexate
    Dosage: 3000 mg/m2, single

Methotrexate
    Dosage: given with hydrocortisone twice x 2
    Indication: non-Hodgkin's Lymphoma

Methotrexate
    Dosage: 1500 mg/m2, single

Prednisolone
    Dosage: 60 mg/m2, daily for 5 days then tapered over 3 days
    Indication: non-Hodgkin's Lymphoma

Prednisolone
    Dosage: 60 mg/m2, daily for 7 days

Rituximab
    Dosage: 1875 mg/m2, every 2-4 weeks for 5 total doses
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: 2 mg/m2, single

Vincristine
    Dosage: 1 mg/m2, single
    Indication: non-Hodgkin's Lymphoma



Possible Vincristine side effects in 18 month old male

Reported by a physician from United States on 2012-07-06

Patient: 18 month old male, weighing 11.4 kg (25.1 pounds)

Reactions: Sepsis, Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Asparaginase
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Dexamethasone Sodium Phosphate
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Dexamethasone Sodium Phosphate

Etoposide
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Lestaurtinib
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Lestaurtinib

Mercaptopurine

Mercaptopurine
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Methotrexate
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Methotrexate

Vincristine

Vincristine
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18



Possible Vincristine side effects in female

Reported by a physician from Germany on 2012-06-28

Patient: female

Reactions: White Blood Cell Count Decreased, C-Reactive Protein Increased, Sepsis, Hypotension, Presyncope, Neutropenia, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Neulasta
    Dosage: daily dose 6 mg, 2 x(29 apr 2012+17 may 2012
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Prednisolone
    Dosage: frequency 1 times in 2 week for 5 days
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-04-30

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Other drugs received by patient: Enoxaparin Natrium; Aspirin; Ramipril; Tiotropium Bromide; Nebivolol; Torsemide; Pantoprazole; Levothyroxine Sodium; Acyclovir; Simvastatin; Trimethoprim + Sulfamethoxazole



Possible Vincristine side effects in 14 year old female

Reported by a physician from United States on 2012-06-28

Patient: 14 year old female, weighing 60.4 kg (132.9 pounds)

Reactions: Stomatitis, Hypotension, Encephalopathy, Acidosis, Hypercalcaemia, Respiratory Failure, Sepsis, Posterior Reversible Encephalopathy Syndrome, Hypocalcaemia, Enterocolitis, Cardiac Arrest

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Ambisome
    Dosage: unk
    Indication: Candida Test Positive
    Start date: 2012-05-20

Calcium Gluconate

Cefepime
    Dosage: unk
    Indication: Klebsiella Infection
    Start date: 2012-05-10

Dexamethasone Sodium Phosphate
    Dosage: 10 mg/m2, bid or iv on days 1-5 and 15-19
    Administration route: Oral
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-04-30

Methotrexate
    Dosage: 8-15 mg (age based dosing) it on days 1 (or up to 72 hours prior to day 1) and 8
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-04-30

Mitoxantrone Hydrochloride
    Dosage: 10 mg/m2, over 30 minutes on days 1 and 2
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-04-30

Pegaspargase
    Dosage: 2500 iu/m2 over 1 hr on days 3 and 17
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-04-30

Temsirolimus
    Dosage: 7.5 mg/m2, over 30 minutes on days i, 8 and 15 (max dose: 15 mg)
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-04-30

Vincristine
    Dosage: 1.5 mg/m2 cyclic (max 2 mg) over i-5 minutes or infusion via mini bag on days 1, 8, i5 and 22
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-04-30



Possible Vincristine side effects in female

Reported by a health professional (non-physician/pharmacist) from Germany on 2012-06-26

Patient: female

Reactions: Syncope, Sepsis, Hypotension, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1493 m
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Neulasta
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Prednisolone
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-04-30

Rituximab
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Vincristine
    Dosage: 3.94 m
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Other drugs received by patient: Simvastatin; Levothyroxine; Ramipril; Acyclovir; Acetylsalicylic Acid SRT; Enoxaparin Sodium; Tiotropium Bromide; Trimethoprim + Sulfamethoxazole; Torsemide; Pantoprazole; Nebivolol



Possible Vincristine side effects in 16 month old female

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-06-26

Patient: 16 month old female

Reactions: Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Carboplatin
    Dosage: 10 mg/kg daily on days 0
    Indication: Brain Neoplasm Malignant

Cisplatin
    Dosage: 3 mg/kg, once daily on day 0 (cecv regimen)
    Indication: Brain Neoplasm Malignant

Cyclophosphamide
    Dosage: 50 mg/kg once daily on day 1 and 2 (cecv regimen)
    Indication: Brain Neoplasm Malignant

Etoposide
    Dosage: 2.5 mg/kg once daily for 5 consecutive days from day 0 (ceiv regimen)

Etoposide
    Dosage: 2.5 mg/kg once daily on days 0, 1, and 2 (cecv regimen)
    Indication: Brain Neoplasm Malignant

Ifosfamide
    Dosage: 50 mg/kg daily for 5 consecutive days from day 0 (ceiv regimen)
    Indication: Brain Neoplasm Malignant

Vincristine
    Dosage: 0.05 mg/kg, 1x/day, day 0 and 7
    Indication: Brain Neoplasm Malignant



Possible Vincristine side effects in 16 month old female

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-06-25

Patient: 16 month old female

Reactions: Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Carboplatin
    Dosage: 10 mg/kg daily on days 0
    Indication: Brain Neoplasm Malignant

Cisplatin
    Dosage: 3 mg/kg, once daily on day 0 (cecv regimen)
    Indication: Brain Neoplasm Malignant

Cyclophosphamide
    Dosage: 50 mg/kg once daily on day 1 and 2 (cecv regimen)
    Indication: Brain Neoplasm Malignant

Etoposide
    Dosage: 2.5 mg/kg once daily on days 0, 1, and 2 (cecv regimen)
    Indication: Brain Neoplasm Malignant

Etoposide
    Dosage: 2.5 mg/kg once daily for 5 consecutive days from day 0 (ceiv regimen)

Ifosfamide
    Dosage: 50 mg/kg daily for 5 consecutive days from day 0 (ceiv regimen)
    Indication: Brain Neoplasm Malignant

Vincristine
    Dosage: 0.05 mg/kg, 1x/day, day 0 and 7
    Indication: Brain Neoplasm Malignant



Possible Vincristine side effects in 10 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21

Patient: 10 year old female

Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2

Cyclophosphamide
    Dosage: 300 mg/m2 as part of cop
    Indication: Burkitt's Lymphoma Stage III

Cytarabine
    Dosage: continuous infusion of 100 mg/m2 daily for 5 days
    Indication: Burkitt's Lymphoma Stage III

Cytarabine
    Dosage: administered once with hydrocortisone as part of cym1

Doxorubicin HCL
    Dosage: as part of copadm1
    Indication: Burkitt's Lymphoma Stage III

Doxorubicin HCL
    Dosage: as part of copadm2

Hydrocortisone
    Dosage: administered once with cytarabine as part of cym1

Hydrocortisone
    Dosage: administered with methotrexate
    Indication: Burkitt's Lymphoma Stage III

Methotrexate
    Dosage: as part of copadm2 and cym1

Methotrexate
    Dosage: administered with hydrocortisone
    Indication: Burkitt's Lymphoma Stage III

Methotrexate
    Dosage: as part of copadm1

Prednisolone
    Dosage: 60 mg/m2/day for 7 days as part of cop
    Indication: Burkitt's Lymphoma Stage III

Prednisolone
    Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2

Rituximab
    Dosage: five total doses; cumulative dose of 1875 mg/m2
    Indication: Burkitt's Lymphoma Stage III

Vincristine
    Dosage: as part of copadm2

Vincristine
    Dosage: as part of copadm1

Vincristine
    Dosage: as part of cop
    Indication: Burkitt's Lymphoma Stage III



Possible Vincristine side effects in 10 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21

Patient: 10 year old female

Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2

Cyclophosphamide
    Dosage: 300 mg/m2 as part of cop
    Indication: Burkitt's Lymphoma Stage III

Cytarabine
    Dosage: continuous infusion of 100 mg/m2 daily for 5 days
    Indication: Burkitt's Lymphoma Stage III

Cytarabine
    Dosage: administered once with hydrocortisone as part of cym1

Doxorubicin HCL
    Dosage: as part of copadm1
    Indication: Burkitt's Lymphoma Stage III

Doxorubicin HCL
    Dosage: as part of copadm2

Hydrocortisone
    Dosage: administered with methotrexate
    Indication: Burkitt's Lymphoma Stage III

Hydrocortisone
    Dosage: administered once with cytarabine as part of cym1

Methotrexate
    Dosage: 3000 mg/m2; administered with hydrocortisone
    Indication: Burkitt's Lymphoma Stage III

Methotrexate
    Dosage: as part of copadm1

Methotrexate
    Dosage: as part of copadm2 and cym1

Prednisolone
    Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2

Prednisolone
    Dosage: 60 mg/m2/day for 7 days as part of cop
    Indication: Burkitt's Lymphoma Stage III

Rituximab
    Dosage: five total doses; cumulative dose of 1875 mg/m2
    Indication: Burkitt's Lymphoma Stage III

Vincristine
    Dosage: as part of copadm1

Vincristine
    Dosage: as part of copadm2

Vincristine
    Dosage: as part of cop
    Indication: Burkitt's Lymphoma Stage III



Possible Vincristine side effects in 10 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21

Patient: 10 year old female

Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 300 mg/m2 as part of cop
    Indication: Burkitt's Lymphoma Stage III

Cyclophosphamide
    Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2

Cytarabine
    Dosage: continuous infusion of 100 mg/m2 daily for 5 days
    Indication: Burkitt's Lymphoma Stage III

Cytarabine
    Dosage: administered once with hydrocortisone as part of cym1

Doxorubicin HCL
    Dosage: as part of copadm1
    Indication: Burkitt's Lymphoma Stage III

Doxorubicin HCL
    Dosage: as part of copadm2

Hydrocortisone
    Dosage: administered once with cytarabine as part of cym1

Hydrocortisone
    Dosage: administered with methotrexate
    Indication: Burkitt's Lymphoma Stage III

Methotrexate
    Dosage: as part of copadm1

Methotrexate
    Dosage: as part of copadm2 and cym1

Methotrexate
    Dosage: administered with hydrocortisone
    Indication: Burkitt's Lymphoma Stage III

Prednisolone
    Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2

Prednisolone
    Dosage: 60 mg/m2/day for 7 days as part of cop
    Indication: Burkitt's Lymphoma Stage III

Rituximab
    Dosage: five total doses; cumulative dose of 1875 mg/m2
    Indication: Burkitt's Lymphoma Stage III

Vincristine
    Dosage: as part of copadm2

Vincristine
    Dosage: as part of cop
    Indication: Burkitt's Lymphoma Stage III

Vincristine
    Dosage: as part of copadm1



Possible Vincristine side effects in 10 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-20

Patient: 10 year old female

Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Pancytopenia, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 250 mg/m2, bid for 6 doses

Cyclophosphamide
    Dosage: 250 mg/m2, bid for 6 doses

Cyclophosphamide
    Dosage: 300 mg/m2, unk
    Indication: Burkitt's Lymphoma Stage III

Cytarabine
    Dosage: 100 mg/m2, for 5 days
    Indication: Burkitt's Lymphoma Stage III

Cytarabine
    Dosage: unknown

Doxorubicin HCL
    Dosage: 30 mg/m2, unk

Doxorubicin HCL
    Dosage: 60 mg/m2, unk
    Indication: Burkitt's Lymphoma Stage III

Hydrocortisone
    Indication: Burkitt's Lymphoma Stage III

Hydrocortisone
    Dosage: intrathecally twice

Hydrocortisone

Hydrocortisone
    Dosage: intrathecally twice

Hydrocortisone
    Dosage: unknwon

Methotrexate
    Dosage: 1500 mg/m2, unk

Methotrexate
    Indication: Burkitt's Lymphoma Stage III

Methotrexate
    Dosage: intrathecally twice

Methotrexate
    Dosage: intrathecally twice

Methotrexate
    Dosage: 1500 mg/m2, unk

Methotrexate
    Dosage: 30000 mg/m2, unk

Methotrexate

Prednisolone
    Dosage: 60 mg/m2, for 5 days, then taper over 3 days

Prednisolone
    Dosage: 60 mg/m2, for 5 days then taper over 3 days

Prednisolone
    Dosage: 60 mg/m2, per day for 7 days
    Indication: Burkitt's Lymphoma Stage III

Rituximab
    Dosage: every 2-4 weeks for 5 total doses with cumulative dose of 1875 mg/m2
    Indication: Burkitt's Lymphoma Stage III

Rituximab
    Dosage: cumulative dose of 1875 mg/m2

Vincristine
    Dosage: 2 mg/m2, unk

Vincristine
    Dosage: 1 mg/m2, unk
    Indication: Burkitt's Lymphoma Stage III

Vincristine
    Dosage: 1 mg/m2, unk



Possible Vincristine side effects in male

Reported by a physician from Italy on 2012-06-14

Patient: male

Reactions: Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Indication: Burkitt's Lymphoma

Etoposide
    Indication: Burkitt's Lymphoma

Methotrexate
    Indication: Burkitt's Lymphoma

Methylprednisolone
    Indication: Burkitt's Lymphoma

Rituximab
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Burkitt's Lymphoma

Other drugs received by patient: Unknown Medication



Possible Vincristine side effects in 68 year old male

Reported by a individual with unspecified qualification from Chile on 2012-06-05

Patient: 68 year old male

Reactions: Rectal Haemorrhage, Sepsis, Pancytopenia, Neutropenia, Ascites

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclosporine
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Methylprednisolone
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-04

Patient:

Reactions: Sepsis, Toxicity To Various Agents

Adverse event resulted in: death

Drug(s) suspected as cause:
Elspar
    Indication: Lymphocytic Leukaemia

Methotrexate
    Dosage: intrathecal
    Indication: Acute Lymphocytic Leukaemia

Prednisolone
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-04

Patient:

Reactions: Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Elspar
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: intrathecal
    Indication: Acute Lymphocytic Leukaemia

Prednisolone
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-04

Patient:

Reactions: Sepsis, Toxicity To Various Agents

Adverse event resulted in: death

Drug(s) suspected as cause:
Elspar
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: intrathecal
    Indication: Acute Lymphocytic Leukaemia

Prednisolone
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012